Stability study of a nanostructured system for the release of the lipid pro-resolution maresin 1

• Grant number: 22/01587-4
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: May 01, 2022
• End date: April 30, 2023
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Fabiana Testa Moura de Carvalho Vicentini
• Grantee: Augusto Pereira Alves
• Host Institution: Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil

Abstract

Maresin 1 (MaR1) is a pro-resolution lipid, that acts both in reducing inflammation and inactivating endogenous mechanisms to resolve/end the inflammatory response (SERHAN et al. 2009). Studies have shown that the treatment with MaR1 solution reduces skin inflammation and oxidative stress induced by UVB radiation (CEZAR et al., 2019) and that MaR1 subverts neuronal function inhibiting the release of neuropeptides, which results in less peripheral inflammation even with intrathecal MaR1 administration, demonstrating novel neuroimmune mechanisms for this lipid (FATTORI et al., 2019). Thus, MaR1 is an endogenous molecule with a great therapeutic perspective. In theory, the delivery of MaR1 by controlled release systems could increase its activity and the duration of its effect, since the activity of pro-resolution lipids is limited by the expression of its receptors by cells. Therefore, to improve its activity, it is necessary to generate the ideal balance between agonist and receptor. Considering these aspects, the ongoing research project entitled: "Development of a nanostructured system for controlled release of pro-resolution lipid: Analgesic effects on inflammation and neuropathy, anti-inflammatory, on infection and tissue repair" (FAPESP, Process 2020/ 07526-1) presents as one of its objectives the development of a nanostructured system based on ferritin for the controlled release of MaR1 in order to increase its effectiveness and duration of effect. The present project, whose main objective is to evaluate whether the incorporation of MaR1 into a ferritin-based nanostructured system is capable of improving the stability of the pro-resolution lipid, strongly contributes to the development stage of the proposed system for MaR1 delivery. So, the development of this proposal will contribute to an integrated, multidisciplinary, innovative research project with potential health benefits.(AU)